A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

Novo Nordisk

Status and phase

Terminated

Phase 2

Conditions

Inflammation

Ulcerative Colitis

Treatments

Drug: placebo

Drug: catridecacog

Study type

Interventional

Funder types

Industry

Identifiers

NCT01706159

2011-001568-22 (EudraCT Number)

U1111-1120-3824 (Other Identifier)

NN8717-3946

Details and patient eligibility

About

This trial is conducted in Europe. The aim of the trial is to investigate the effect of recombinant factor XIII (rFXIII) administered to subjects with mild to moderate active ulcerative colitis (UC).

Enrollment

20 patients

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of ulcerative colitis for at least 3 months from the time of initial diagnosis. The diagnosis must have been confirmed by historical endoscopy and histology. The severity of disease must have been confirmed by endoscopy at screening
Currently receiving oral aminosalicylates at approved doses of at least 2g/day for at least 6 weeks. Doses of oral aminosalicylates should be stable for at least two weeks prior to dosing (Visit 2)

Exclusion criteria

Diagnosis of UC limited to the rectum (ulcerative proctitis only, defined as less than 15 cm from the anal verge)
Requiring hospitalisation for current episode of severe UC
Use of biologic therapies for the treatment of UC within 12 weeks prior to dosing (Visit 2)
Treatment failures to anti-tumour necrosis factor-alfa (anti-TNF-a) agents (e.g. infliximab, adalimumab)
Use of immunosuppressant agents (e.g. azathioprine) within 4 weeks prior to dosing (Visit 2)
Use of corticosteroids (oral, intravenous (i.v.), intramuscular (i.m.), or rectal ) within 14 days prior to dosing (Visit 2)
Use of enemas (corticosteroid or aminosalicylate) within 14 days prior to screening (Visit 1)
Use of cyclosporine, tacrolimus, D-penicillamine, leflunomide, methotrexate, mycophenolate mofetil, or thalidomide within 4 weeks prior to dosing (Visit 2)
Currently receiving total parenteral nutrition